The Cell & Gene Collective was set up by OVID Health in 2020. It is an alliance of five biopharmaceutical companies who wish to support the NHS and policymakers in delivering appropriately assessed, commissioned, and delivered cell and gene therapies to patients.
As well as making a distinctive case for access reform for these advanced therapies, the Collective raises awareness among politicians and policy influencers on the promise of CGTs and the patient voice on this topic.
The Cell & Gene Collective’s membership is comprised of: Bayer, Johnson & Johnson, Kite (a Gilead company), Orchard Therapeutics and Vertex Pharmaceuticals.
